Endocytosis and trafficking of PRL receptor isoforms

PRL 受体亚型的内吞作用和运输

基本信息

  • 批准号:
    6681787
  • 负责人:
  • 金额:
    $ 24.7万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2003
  • 资助国家:
    美国
  • 起止时间:
    2003-06-01 至 2007-05-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Ligand binding to many membrane receptors initiates internalization of both ligand and receptor. This process has been shown to result in multiple potential fates, including recycling of receptors back to the surface, degradation of ligand and/or receptor by lysosomes or proteasomes resulting in down-regulation of displayed receptor, or modulation of signaling by temporally and spatially regulating the location of the receptor. Endocytosis is therefore a major modulator of cell responsiveness over the short term. We are only beginning to understand the molecular events regulating these processes for other classes of membrane receptors. Different receptor isoforms with distinct signaling capacities, such as those for the prolactin (PRL) receptor, are expressed on the same target cells, but at different levels depending on target and environment. Thus knowledge of these processes and net effect on PRL action is essential to understanding PRL function at its targets in physiologic and pathologic states. Our data demonstrate that PRL receptor isoforms are internalized at different rates, that ligand binding leads to down regulation of the "long" but not the "short" PRLR isoform, and that PRL-induced activation of c-Src is important for internalization of the "long" but not the "short" PRLR isoform. We hypothesize that ligand binding to the "long" and "short" PRLR isoforms results in receptor endocytosis and processing by distinct mechanisms dictated by sequences in the cytoplasmic domain, and that these events both are determined by transduced signals, and modulate net output. We propose to: 1. Compare endocytic pathways for each PRLR isoform using confocal microscopy, dominant negative constructs, and biochemical fractionation, and identify domains of the PRL receptors which are responsible. 2. Examine post-internalization sorting and fate of receptor isoforms in constitutive and ligand-induced endocytosis using selective inhibitors, biochemical and immunohistochemical approaches, and identify PRL receptor domains which participate. 3. Characterize the requirements for signal transduction in internalization and trafficking of the isoforms, and determine the relationship of endocytosis to signal transduction through several pathways. 4. Determine the role of dimerization in this process, and the effect of homo- vs. hetero-dimerization using chimeric receptors and PRL antagonists.
描述(由申请人提供):配体与许多膜受体结合,启动配体和受体的内化。这一过程已被证明会导致多种潜在的命运,包括受体再循环回到表面,溶酶体或蛋白酶体降解配体和/或受体,导致显示受体的下调,或通过时间和空间调节受体的位置来调节信号传导。因此,内吞作用在短期内是细胞反应性的主要调节因素。我们才刚刚开始了解其他类膜受体调节这些过程的分子事件。不同的受体异构体具有不同的信号传导能力,如催乳素(PRL)受体,在相同的靶细胞上表达,但根据目标和环境的不同,表达水平不同。因此,了解这些过程和对PRL作用的净效应对于理解PRL在生理和病理状态下对其靶点的功能至关重要。我们的数据表明,PRL受体异构体以不同的速率内化,配体结合导致“长”而非“短”PRLR异构体的下调,PRL诱导的c-Src活化对“长”而非“短”PRLR异构体的内化很重要。我们假设配体与“长”和“短”PRLR异构体结合导致受体内吞作用和加工的不同机制由细胞质域中的序列决定,这些事件都是由转导信号决定的,并调节净输出。我们建议:1。使用共聚焦显微镜、显性阴性结构体和生化分离比较每个PRLR亚型的内吞途径,并确定负责PRL受体的结构域。2. 使用选择性抑制剂、生化和免疫组织化学方法检查内化后的受体亚型在组成型和配体诱导的内吞作用中的分类和命运,并确定参与的PRL受体结构域。3. 表征同种异构体内化和运输对信号转导的要求,并确定内吞作用与信号转导的关系,通过几种途径。4. 利用嵌合受体和PRL拮抗剂确定二聚化在这一过程中的作用,以及同性与异性二聚化的影响。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

LINDA A. SCHULER其他文献

LINDA A. SCHULER的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('LINDA A. SCHULER', 18)}}的其他基金

Matrix density promotes pro-tumorigenc hormone actions in breast cancer
基质密度促进乳腺癌中促肿瘤激素的作用
  • 批准号:
    9228974
  • 财政年份:
    2014
  • 资助金额:
    $ 24.7万
  • 项目类别:
Matrix density promotes pro-tumorigenc hormone actions in breast cancer
基质密度促进乳腺癌中促肿瘤激素的作用
  • 批准号:
    9379069
  • 财政年份:
    2014
  • 资助金额:
    $ 24.7万
  • 项目类别:
Prolactin: mammary progenitors and tumor initiating cells in luminal carcinomas
催乳素:乳腺祖细胞和管腔癌中的肿瘤起始细胞
  • 批准号:
    8677796
  • 财政年份:
    2011
  • 资助金额:
    $ 24.7万
  • 项目类别:
Prolactin: mammary progenitors and tumor initiating cells in luminal carcinomas
催乳素:乳腺祖细胞和管腔癌中的肿瘤起始细胞
  • 批准号:
    8298139
  • 财政年份:
    2011
  • 资助金额:
    $ 24.7万
  • 项目类别:
Prolactin: mammary progenitors and tumor initiating cells in luminal carcinomas
催乳素:乳腺祖细胞和管腔癌中的肿瘤起始细胞
  • 批准号:
    8185605
  • 财政年份:
    2011
  • 资助金额:
    $ 24.7万
  • 项目类别:
Prolactin: mammary progenitors and tumor initiating cells in luminal carcinomas
催乳素:乳腺祖细胞和管腔癌中的肿瘤起始细胞
  • 批准号:
    8469745
  • 财政年份:
    2011
  • 资助金额:
    $ 24.7万
  • 项目类别:
Endocytosis and trafficking of PRL receptor isoforms
PRL 受体亚型的内吞作用和运输
  • 批准号:
    7071221
  • 财政年份:
    2003
  • 资助金额:
    $ 24.7万
  • 项目类别:
Endocytosis and trafficking of PRL receptor isoforms
PRL 受体亚型的内吞作用和运输
  • 批准号:
    6879954
  • 财政年份:
    2003
  • 资助金额:
    $ 24.7万
  • 项目类别:
Endocytosis and trafficking of PRL receptor isoforms
PRL 受体亚型的内吞作用和运输
  • 批准号:
    6752447
  • 财政年份:
    2003
  • 资助金额:
    $ 24.7万
  • 项目类别:
MAMMARY PROLACTIN PRODUCTION AND BREAST CANCER
乳房催乳素的产生与乳腺癌
  • 批准号:
    6376804
  • 财政年份:
    1999
  • 资助金额:
    $ 24.7万
  • 项目类别:

相似海外基金

Non-canonical chimeric proteins generated during Adenovirus infection
腺病毒感染期间产生的非典型嵌合蛋白
  • 批准号:
    10448505
  • 财政年份:
    2021
  • 资助金额:
    $ 24.7万
  • 项目类别:
Non-canonical chimeric proteins generated during Adenovirus infection
腺病毒感染期间产生的非典型嵌合蛋白
  • 批准号:
    10312411
  • 财政年份:
    2021
  • 资助金额:
    $ 24.7万
  • 项目类别:
Increasing efficiency in formation of chimeric proteins
提高嵌合蛋白形成的效率
  • 批准号:
    561998-2021
  • 财政年份:
    2021
  • 资助金额:
    $ 24.7万
  • 项目类别:
    University Undergraduate Student Research Awards
Decoration and Dimerization of Chimeric Proteins Mediated by Coiled-Coil Interactions
卷曲螺旋相互作用介导的嵌合蛋白的修饰和二聚化
  • 批准号:
    537306-2018
  • 财政年份:
    2019
  • 资助金额:
    $ 24.7万
  • 项目类别:
    Collaborative Research and Development Grants
Exploring the therapeutic potential of chimeric proteins
探索嵌合蛋白的治疗潜力
  • 批准号:
    1947736
  • 财政年份:
    2017
  • 资助金额:
    $ 24.7万
  • 项目类别:
    Studentship
TARGETING PROTEIN INTERACTIONS AND DESIGNING CHIMERIC PROTEINS
靶向蛋白质相互作用并设计嵌合蛋白质
  • 批准号:
    8364271
  • 财政年份:
    2011
  • 资助金额:
    $ 24.7万
  • 项目类别:
Therapeutic peanut allergen Fc gamma chimeric proteins to treat peanut allergy
用于治疗花生过敏的治疗性花生过敏原 Fc γ 嵌合蛋白
  • 批准号:
    8444422
  • 财政年份:
    2010
  • 资助金额:
    $ 24.7万
  • 项目类别:
Cat allergen-human Fc-gamma1 chimeric proteins to treat cat allergy
猫过敏原-人Fc-gamma1嵌合蛋白治疗猫过敏
  • 批准号:
    7907314
  • 财政年份:
    2010
  • 资助金额:
    $ 24.7万
  • 项目类别:
TARGETING PROTEIN INTERACTIONS AND DESIGNING CHIMERIC PROTEINS
靶向蛋白质相互作用并设计嵌合蛋白质
  • 批准号:
    8171849
  • 财政年份:
    2010
  • 资助金额:
    $ 24.7万
  • 项目类别:
Therapeutic peanut allergen Fc gamma chimeric proteins to treat peanut allergy
用于治疗花生过敏的治疗性花生过敏原 Fc γ 嵌合蛋白
  • 批准号:
    8313432
  • 财政年份:
    2010
  • 资助金额:
    $ 24.7万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了